Evidence map›Paper›PMID 23422357›Full record

Trial reportJournal of Alzheimer's disease : JAD2013

Caffeine and cognitive decline in elderly women at high vascular risk.

Marie-Noël Vercambre, Claudine Berr, Karen Ritchie, Jae H Kang

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of Alzheimer's disease : JAD, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 4 pooled it
6.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Review
  6. Review
  7. Observational
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Time to Recover From Daily Caffeine Intake.Frontiers in nutrition · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Marie-Noël VercambreMGEN Foundation for Public Health, Paris, France. mvercambre@mgen.fr
Claudine Berr
Karen Ritchie
Jae H Kang
Inserm · FRBrigham and Women's Hospital · USMutuelle Générale de l'Éducation Nationale · FR

Funding

TRIAL OF ANTIOXIDANT THERAPY OF CVD IN WOMENR01HL046959 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MANSON, JOANN ELISABETH · 1993 to 2005
$3.6M
TRIALS OF PREVENTION OF COGNITIVE DECLINE IN WOMEN AND MR01AG015933 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI GRODSTEIN, FRANCINE · 1998 to 2007
$2.4M
NHLBI NIH HHS HL046959NHLBI NIH HHS R01 HL046959NIA NIH HHS AG15933NIA NIH HHS R01 AG015933
6 · The paper itself

Abstract

backgroundPersons with vascular disorders are at higher risk of cognitive decline.

objectiveTo determine whether caffeine may be associated with cognitive decline reduction in elderly at high vascular risk.

methodsWe included 2,475 women aged 65+ years in the Women's Antioxidant Cardiovascular Study, a randomized trial of antioxidants and B vitamins for cardiovascular disease secondary prevention. We ascertained regular caffeine intake at baseline (1995-1996) using a validated 116 item-food frequency questionnaire. From 1998-2000 to 2005-2006, we administered four telephone cognitive assessments at two-year intervals evaluating global cognition, verbal memory, and category fluency. The primary outcome was the change in global cognitive score, which was the average of the z-scores of all tests. We used generalized linear models for repeated measures that were adjusted for various sociodemographic, health, and lifestyle factors to evaluate the difference in cognitive decline rates across quintiles of caffeine intake.

resultsWe observed significantly slower rates of cognitive decline with increasing caffeine intake (p-trend = 0.02). The rate difference between the highest and lowest quintiles of usual caffeine intake (>371 versus <30 mg/day) was equivalent to that observed between those who were 7 years apart in age (p = 0.006). Consumption of caffeinated coffee was significantly related to slower cognitive decline (p-trend = 0.05), but not other caffeinated products (e.g., decaf, tea, cola, chocolate). We conducted interaction analyses and observed stronger associations in women assigned to vitamin B supplementation (p-interaction = 0.02).

conclusionsCaffeine intake was related to moderately better cognitive maintenance over 5 years in older women with vascular disorders.

Indexed as

AgedAgingCaffeineCentral Nervous System StimulantsCerebrovascular DisordersCognitionCognition DisordersCohort StudiesDietary SupplementsDisease ProgressionFemaleHumansLinear ModelsLongitudinal StudiesMiddle AgedMultivariate AnalysisCaffeineCentral Nervous System StimulantsVitamin B ComplexVitamins

Identifiers

PMID23422357
PMCPMC3807252
OpenAlexW1508789589

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.